Review

The utility of α-synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature

Memory Disorders Research Group, Department of Neurology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

^‡These authors contributed equally

Search for more papers by this author

Bea Kuiperij^‡

Department of Neurology, Department of Laboratory Medicine, Donders Institute for Brain, Cognition & Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands

^‡These authors contributed equally

Search for more papers by this author

Omar Mukhtar Ali El-Agnaf

College of Science and Engineering, Hamid Bin Khalifa University, Qatar Foundation, Education City, PO Box 5825 Doha, Qatar

Search for more papers by this author

Sebastian Engelborghs

Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp & Department of Neurology & Memory Clinic, Hospital Network Antwerp (ZNA) Middelheim and Hoge Beuken, Antwerp, Belgium

Search for more papers by this author

Sanna-Kaisa Herukka

Institute of Clinical Medicine – Neurology University of Eastern Finland School of Medicine, Kuopio, Finland

Search for more papers by this author

Lucilla Parnetti

Centro Disturbi della Memoria- Unità Valutativa Alzheimer, Clinica Neurologica, Università di Perugia, Italy

Search for more papers by this author

Irena Rektorova

Applied Neuroscience Research Group, CEITEC MU, Masaryk University, Brno, Czech Republic

Search for more papers by this author

Eugeen Vanmechelen

ADx NeuroSciences, VIB-Bioincubator, Technologiepark Zwijnaarde 4, 9052 Ghent, Belgium

Search for more papers by this author

Elisabeth Kapaki

National & Kapodistrian University of Athens, School of Medicine, 1st Department of Neurology, Eginition Hospital, Athens, Greece

Search for more papers by this author

Marcel Verbeek

Department of Neurology, Department of Laboratory Medicine, Donders Institute for Brain, Cognition & Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands

Search for more papers by this author

Brit Mollenhauer

*Author for correspondence:

E-mail Address: brit.mollenhauer@paracelsus-kliniken.de

Paracelsus-Elena-Klinik, Kassel & University Medical Center (Departments of Neuropathology & Neurosurgery), Georg-August University Goettingen, Germany

Search for more papers by this author

Published Online:28 Aug 2015https://doi.org/10.2217/BMM.14.105

View article

Abstract

The discovery of α-synuclein (α-syn) as a major component of Lewy bodies, neuropathological hallmark of Parkinson's disease (PD), dementia with Lewy bodies and of glial inclusions in multiple system atrophy initiated the investigation of α-syn as a biomarker in cerebrospinal fluid (CSF). Due to the involvement of the periphery in PD the quantification of α-syn in peripheral fluids such as serum, plasma and saliva has been investigated as well. We review how the development of multiple assays for the quantification of α-syn has yielded novel insights into the variety of α-syn species present in the different fluids; the optimal preanalytical conditions required for robust quantification and the potential clinical value of α-syn as biomarker. We also suggest future approaches to use of CSF α-syn in neurodegenerative diseases.

Keywords:

References

1 Del Tredici K, Hawkes CH, Ghebremedhin E, Braak H. Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson's disease. Acta Neuropathol. 119(6), 703–713 (2010).
MedlineGoogle Scholar
2 Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 55(3), 181–184 (1992).
Medline CASGoogle Scholar
3 El-Agnaf OM, Salem SA, Paleologou KE et al. Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J. 17(13), 1945–1947 (2003).
Medline CASGoogle Scholar
4 Mollenhauer B, El-Agnaf OM, Marcus K, Trenkwalder C, Schlossmacher MG. Quantification of alpha-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies. Biomark. Med. 4(5), 683–699 (2010).
CASGoogle Scholar
5 Ueda K, Saitoh T, Mori H. Tissue-dependent alternative splicing of mRNA for NACP, the precursor of non-A beta component of Alzheimer's disease amyloid. Biochem. Biophys. Res. Commun. 205(2), 1366–1372 (1994).
Medline CASGoogle Scholar
6 Campion D, Martin C, Heilig R et al. The NACP/synuclein gene: chromosomal assignment and screening for alterations in Alzheimer disease. Genomics 26(2), 254–257 (1995).
Medline CASGoogle Scholar
7 Mollenhauer B, Cullen V, Kahn I et al. Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp. Neurol. 213(2), 315–325 (2008).
Medline CASGoogle Scholar
8 Tokuda T, Salem SA, Allsop D et al. Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem. Biophys. Res. Commun. 349(1), 162–166 (2006).
Medline CASGoogle Scholar
9 Van Geel WJ, Abdo WF, Melis R, Williams S, Bloem BR, Verbeek MM. A more efficient enzyme-linked immunosorbent assay for measurement of alpha-synuclein in cerebrospinal fluid. J. Neurosci. Methods 168(1), 182–185 (2008).
Medline CASGoogle Scholar
10 Tokuda T, Qureshi MM, Ardah MT et al. Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 75(20), 1766–1772 (2010).
Medline CASGoogle Scholar
11 Parnetti L, Chiasserini D, Bellomo G et al. Cerebrospinal fluid Tau/alpha-synuclein ratio in Parkinson's disease and degenerative dementias. Mov. Disord. 26(8), 1428–1435 (2011).
MedlineGoogle Scholar
12 Parnetti L, Farotti L, Eusebi P et al. Differential role of CSF alpha-synuclein species, tau, and Abeta42 in Parkinson's disease. Front. Aging Neurosci. 6, 53 (2014).
MedlineGoogle Scholar
13 Reesink FE, Lemstra AW, Van Dijk KD et al. CSF alpha-synuclein does not discriminate dementia with Lewy bodies from Alzheimer's disease. J. Alzheimers Dis. 22(1), 87–95 (2010).
Medline CASGoogle Scholar
14 Aerts MB, Esselink RA, Abdo WF, Bloem BR, Verbeek MM. CSF alpha-synuclein does not differentiate between parkinsonian disorders. Neurobiol. Aging 33(2), 430.e1–e3 (2012).
CASGoogle Scholar
15 Park MJ, Cheon SM, Bae HR, Kim SH, Kim JW. Elevated levels of alpha-synuclein oligomer in the cerebrospinal fluid of drug-naive patients with Parkinson's disease. J. Clin. Neurol. 7(4), 215–222 (2011).
MedlineGoogle Scholar
16 Aasly JO, Johansen KK, Bronstad G et al. Elevated levels of cerebrospinal fluid alpha-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers. Front. Aging Neurosci. 6, 248 (2014).
MedlineGoogle Scholar
17 Tinsley RB, Kotschet K, Modesto D et al. Sensitive and specific detection of alpha-synuclein in human plasma. J. Neurosci. Res. 88(12), 2693–2700 (2010).
Medline CASGoogle Scholar
18 Duran R, Barrero FJ, Morales B, Luna JD, Ramirez M, Vives F. Plasma alpha-synuclein in patients with Parkinson's disease with and without treatment. Mov. Disord. 25(4), 489–493 (2010).
MedlineGoogle Scholar
19 Tateno F, Sakakibara R, Kawai T, Kishi M, Murano T. Alpha-synuclein in the cerebrospinal fluid differentiates synucleinopathies (Parkinson disease, dementia with Lewy bodies, multiple system atrophy) from Alzheimer disease. Alzheimer Dis. Assoc. Disord. 26(3), 213–216 (2012).
Medline CASGoogle Scholar
20 Brighina L, Prigione A, Begni B et al. Lymphomonocyte alpha-synuclein levels in aging and in Parkinson disease. Neurobiol. Aging. 31(5), 884–885 (2010).
Medline CASGoogle Scholar
21 Su E, Bell MJ, Wisniewski SR et al. alpha-Synuclein levels are elevated in cerebrospinal fluid following traumatic brain injury in infants and children: the effect of therapeutic hypothermia. Dev. Neurosci. 32(5–6), 385–395 (2010).
Medline CASGoogle Scholar
22 Laske C, Fallgatter AJ, Stransky E, Hagen K, Berg D, Maetzler W. Decreased alpha-synuclein serum levels in patients with Lewy body dementia compared with Alzheimer's disease patients and control subjects. Dement. Geriatr. Cogn. Disord. 31(6), 413–416 (2011).
Medline CASGoogle Scholar
23 Wennstrom M, Surova Y, Hall S et al. Low CSF levels of both alpha-synuclein and the alpha-synuclein cleaving enzyme neurosin in patients with synucleinopathy. PLoS ONE 8(1), e53250 (2013).
MedlineGoogle Scholar
24 Wang H, Wang K, Xu W et al. Cerebrospinal fluid alpha-synuclein levels are elevated in multiple sclerosis and neuromyelitis optica patients during replase. J. Neurochem. 122(1), 19–23 (2012).
MedlineGoogle Scholar
25 Bidinosti M, Shimshek DR, Mollenhauer B et al. Novel one-step immunoassays to quantify alpha-synuclein: applications for biomarker development and high-throughput screening. J. Biol. Chem. 287(40), 33691–33705 (2012).
Medline CASGoogle Scholar
26 Emmanouilidou E, Elenis D, Papasilekas T et al. Assessment of alpha-synuclein secretion in mouse and human brain parenchyma. PLoS ONE 6(7), e22225 (2011).
Medline CASGoogle Scholar
27 Lee HJ, Bae EJ, Jang A et al. Enzyme-linked immunosorbent assays for alpha-synuclein with species and multimeric state specificities. J. Neurosci. Methods 199(2), 249–257 (2011).
Medline CASGoogle Scholar
28 Kovacs GG, Wagner U, Dumont B et al. An antibody with high reactivity for disease-associated alpha-synuclein reveals extensive brain pathology. Acta Neuropathol. 124(1), 37–50 (2012).
Medline CASGoogle Scholar
29 Ohrfelt A, Grognet P, Andreasen N et al. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss? Neurosci. Lett. 450(3), 332–335 (2009).
MedlineGoogle Scholar
30 Kruse N, Vanmechelen E, Schlossmacher MG et al. Sensitive multiplex quantification of alpha-Synuclein, DJ-1, beta-Amyloid 1–42 and Tau protein in human biological fluids based on chemiluminescence detection. Neurodegener. Dis. 11(Suppl. 1) (2013).
Google Scholar
31 Kruse N, Schulz-Schaeffer WJ, Schlossmacher MG, Mollenhauer B. Development of electrochemiluminescence-based singleplex and multiplex assays for the quantification of alpha-synuclein and other proteins in cerebrospinal fluid. Methods 56(4), 514–518 (2012).
Medline CASGoogle Scholar
32 Kasuga K, Tokutake T, Ishikawa A et al. Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 81(6), 608–610 (2010).
MedlineGoogle Scholar
33 Hong Z, Shi M, Chung KA et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 133(Pt 3), 713–726 (2010).
MedlineGoogle Scholar
34 Mollenhauer B, Trautmann E, Taylor P et al. Total CSF alpha-synuclein is lower in de novo Parkinson patients than in healthy subjects. Neurosci. Lett. 532, 44–48 (2013).
Medline CASGoogle Scholar
35 Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Doring F, Trenkwalder C, Schlossmacher MG. alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol. 10(3), 230–240 (2011).
Medline CASGoogle Scholar
36 Korff A, Liu C, Ginghina C, Shi M, Zhang J. Alzheimer's Disease Neuroimaging I. alpha-Synuclein in cerebrospinal fluid of Alzheimer's disease and mild cognitive impairment. J. Alzheimers Dis. 36(4), 679–688 (2013).
Medline CASGoogle Scholar
37 Toledo JB, Korff A, Shaw LM, Trojanowski JQ, Zhang J. CSF alpha-synuclein improves diagnostic and prognostic performance of CSF tau and Abeta in Alzheimer's disease. Acta Neuropathol. 126(5), 683–697 (2013).
Medline CASGoogle Scholar
38 Hall S, Ohrfelt A, Constantinescu R et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or Parkinsonian disorders. Arch. Neurol. 69(11), 1445–1452 (2012).
MedlineGoogle Scholar
39 Slaets S, Vanmechelen E, Le Bastard N et al. Increased CSF alpha-synuclein levels in Alzheimer's disease: correlation with tau levels. Alzheimers Dement. 10(5, Suppl.), S290–S298 (2014).
MedlineGoogle Scholar
40 Kang JH, Irwin DJ, Chen-Plotkin AS et al. Association of cerebrospinal fluid beta-amyloid 1–42, T-tau, P-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA neurol. 70(10), 1277–1287 (2013).
MedlineGoogle Scholar
41 Mondello S, Constantinescu R, Zetterberg H, Andreasson U, Holmberg B, Jeromin A. CSF alpha-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders. Parkinsonism. Relat. Disord. 20(4), 382–387 (2014).
MedlineGoogle Scholar
42 El-Agnaf OM, Irvine GB. Review: formation and properties of amyloid-like fibrils derived from alpha-synuclein and related proteins. J. Struct. Biol. 130(2–3), 300–309 (2000).
Medline CASGoogle Scholar
43 Sharon R, Bar-Joseph I, Frosch MP, Walsh DM, Hamilton JA, Selkoe DJ. The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron 37(4), 583–595 (2003).
Medline CASGoogle Scholar
44 Paleologou KE, Kragh CL, Mann DM et al. Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies. Brain 132(Pt 4), 1093–1101 (2009).
MedlineGoogle Scholar
45 Klucken J, Outeiro TF, Nguyen P, Mclean PJ, Hyman BT. Detection of novel intracellular alpha-synuclein oligomeric species by fluorescence lifetime imaging. FASEB J. 20(12), 2050–2057 (2006).
Medline CASGoogle Scholar
46 El-Agnaf OM, Salem SA, Paleologou KE et al. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J. 20(3), 419–425 (2006).
Medline CASGoogle Scholar
47 Fujiwara H, Hasegawa M, Dohmae N et al. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell. Biol. 4(2), 160–164 (2002).
Medline CASGoogle Scholar
48 Anderson JP, Walker DE, Goldstein JM et al. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem. 281(40), 29739–29752 (2006).
Medline CASGoogle Scholar
49 Games D, Seubert P, Rockenstein E et al. Axonopathy in an alpha-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal-truncated alpha-synuclein. Am. J. Pathol. 182(3), 940–953 (2013).
Medline CASGoogle Scholar
50 El-Agnaf OM, Walsh DM, Allsop D. Soluble oligomers for the diagnosis of neurodegenerative diseases. Lancet Neurol. 2(8), 461–462 (2003).
MedlineGoogle Scholar
51 Bartels T, Choi JG, Selkoe DJ. alpha-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 477(7362), 107–110 (2011).
Medline CASGoogle Scholar
52 Gorostidi A, Bergareche A, Ruiz-Martinez J et al. Alpha-synuclein levels in blood plasma from LRRK2 mutation carriers. PLoS ONE 7(12), e52312 (2012).
Medline CASGoogle Scholar
53 Lindersson E, Beedholm R, Hojrup P et al. Proteasomal inhibition by alpha-synuclein filaments and oligomers. J. Biol. Chem. 279(13), 12924–12934 (2004).
Medline CASGoogle Scholar
54 Unterberger U, Lachmann I, Voigtlander T et al. Detection of disease-associated alpha-synuclein in the cerebrospinal fluid: a feasibility study. Clin. Neuropathol. 33(5), 329–334 (2014).
MedlineGoogle Scholar
55 Okochi M, Walter J, Koyama A et al. Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein. J. Biol. Chem. 275(1), 390–397 (2000).
Medline CASGoogle Scholar
56 Chen L, Feany MB. Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat. Neurosci. 8(5), 657–663 (2005).
Medline CASGoogle Scholar
57 Foulds PG, Mitchell JD, Parker A et al. Phosphorylated alpha-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease. FASEB J. 25(12), 4127–4137 (2011).
Medline CASGoogle Scholar
58 Wang Y, Shi M, Chung KA et al. Phosphorylated alpha-synuclein in Parkinson's disease. Sci. Transl. Med. 4(121), 121ra120 (2012).
Google Scholar
59 Fernandez E, Garcia-Moreno JM, Martin De Pablos A, Chacon J. May the evaluation of nitrosative stress through selective increase of 3-nitrotyrosine proteins other than nitroalbumin and dominant tyrosine-125/136 nitrosylation of serum alpha-synuclein serve for diagnosis of sporadic Parkinson's disease? Antioxid. Redox. Signal. 19(9), 912–918 (2013).
Medline CASGoogle Scholar
60 Chavez J, Bajrami B, Copeland M et al. Development of quantitative methods to measure alpha-synuclein and related subspecies in CSF as candidate biomarkers for Parkinson's disease progression. Neurodegener. Dis. 11(Suppl. 1), (2013).
Google Scholar
61 Van Dijk KD, Bidinosti M, Weiss A, Raijmakers P, Berendse HW, Van De Berg WD. Reduced alpha-synuclein levels in cerebrospinal fluid in Parkinson's disease are unrelated to clinical and imaging measures of disease severity. Eur. J. Neurol. 21(3), 388–394 (2014).
Medline CASGoogle Scholar
62 Blennow K, Wallin A, Hager O. Low frequency of post-lumbar puncture headache in demented patients. Acta Neurol. Scand. 88(3), 221–223 (1993).
Medline CASGoogle Scholar
63 Braak H, Del Tredici K, Rub U, De Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24(2), 197–211 (2003).
MedlineGoogle Scholar
64 Barbour R, Kling K, Anderson JP et al. Red blood cells are the major source of alpha-synuclein in blood. Neurodegener. Dis. 5(2), 55–59 (2008).
Medline CASGoogle Scholar
65 Scherzer CR, Grass JA, Liao Z et al. GATA transcription factors directly regulate the Parkinson's disease-linked gene alpha-synuclein. Proc. Natl Acad. Sci. USA 105(31), 10907–10912 (2008).
Medline CASGoogle Scholar
66 Mollenhauer B, Trautmann E, Otte B et al. alpha-Synuclein in human cerebrospinal fluid is principally derived from neurons of the central nervous system. J. Neural. Transm. 119(7), 739–746 (2012).
Medline CASGoogle Scholar
67 Mata IF, Shi M, Agarwal P et al. SNCA variant associated with Parkinson disease and plasma alpha-synuclein level. Arch. Neurol. 67(11), 1350–1356 (2010).
MedlineGoogle Scholar
68 Besong-Agbo D, Wolf E, Jessen F et al. Naturally occurring alpha-synuclein autoantibody levels are lower in patients with Parkinson disease. Neurology 80(2), 169–175 (2013).
Medline CASGoogle Scholar
69 Devic I, Hwang H, Edgar JS et al. Salivary alpha-synuclein and DJ-1: potential biomarkers for Parkinson's disease. Brain 134(Pt 7), e178 (2011).
MedlineGoogle Scholar
70 Bolstad N, Warren DJ, Nustad K. Heterophilic antibody interference in immunometric assays. Best Pract. Res. Clin. Endocrinol. Metab. 27(5), 647–661 (2013).
Medline CASGoogle Scholar
71 Sehlin D, Sollvander S, Paulie S et al. Interference from heterophilic antibodies in amyloid-beta oligomer ELISAs. J. Alzheimers Dis. 21(4), 1295–1301 (2010).
Medline CASGoogle Scholar
72 Bruggink KA, Kuiperij HB, Ekholm-Pettersson F, Verbeek MM. Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 77(5), 510; author reply 510–511 (2011).
MedlineGoogle Scholar
73 Kasuga K, Nishizawa M, Ikeuchi T. alpha-synuclein as CSF and blood biomarker of dementia with Lewy bodies. Int. J. Alzheimers Dis. 2012, 437025 (2012).
MedlineGoogle Scholar
74 Kapaki E, Paraskevas GP, Emmanouilidou E, Vekrellis K. The diagnostic value of CSF alpha-synuclein in the differential diagnosis of dementia with Lewy bodies vs. normal subjects and patients with Alzheimer's disease. PLoS ONE 8(11), e81654 (2013).
MedlineGoogle Scholar
75 Teunissen CE, Tumani H, Bennett JL et al. Consensus Guidelines for CSF and Blood Biobanking for CNS Biomarker studies. Mult. Scler. Int. 2011, 246412 (2011).
MedlineGoogle Scholar
76 Vakharia VN, Lote H. Introduction of Sprotte needles to a single-centre acute neurology service: before and after study. JRSM Short Rep. 3(12), 82 (2012).
MedlineGoogle Scholar
77 Del Campo M, Mollenhauer B, Bertolotto A et al. Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. Biomark. Med. 6(4), 419–430 (2012).
CASGoogle Scholar
78 Noguchi-Shinohara M, Tokuda T, Yoshita M et al. CSF alpha-synuclein levels in dementia with Lewy bodies and Alzheimer's disease. Brain Res. 1251, 1–6 (2009).
Medline CASGoogle Scholar
79 Mignini F, Bronzetti E, Felici L et al. Dopamine receptor immunohistochemistry in the rat choroid plexus. J. Auton. Pharmacol. 20(5–6), 325–332 (2000).
Medline CASGoogle Scholar
80 Wennstrom M, Londos E, Minthon L, Nielsen HM. Altered CSF orexin and alpha-synuclein levels in dementia patients. J. Alzheimers. Dis. 29(1), 125–132 (2012).
MedlineGoogle Scholar
81 Kang JE, Lim MM, Bateman RJ et al. Amyloid-beta dynamics are regulated by orexin and the sleep–wake cycle. Science 326(5955), 1005–1007 (2009).
Medline CASGoogle Scholar
82 Bateman RJ, Wen G, Morris JC, Holtzman DM. Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. Neurology 68(9), 666–669 (2007).
Medline CASGoogle Scholar
83 Spies PE, Slats D, Rikkert MG, Tseng J, Claassen JA, Verbeek MM. CSF alpha-synuclein concentrations do not fluctuate over hours and are not correlated to amyloid beta in humans. Neurosci. Lett. 504(3), 336–338 (2011).
Medline CASGoogle Scholar
84 Spies PE, Melis RJ, Sjogren MJ, Rikkert MG, Verbeek MM. Cerebrospinal fluid alpha-synuclein does not discriminate between dementia disorders. J. Alzheimers Dis. 16(2), 363–369 (2009).
Medline CASGoogle Scholar
85 Shi M, Bradner J, Hancock AM et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann. Neurol. 69(3), 570–580 (2011).
Medline CASGoogle Scholar
86 Herbert MK, Aerts MB, Beenes M et al. CSF neurofilament light chain but not FLT3 ligand discriminates Parkinsonian disorders. Front Neurol. 6, 91 (2015).
MedlineGoogle Scholar
87 Abdo WF, Bloem BR, Van Geel WJ, Esselink RA, Verbeek MM. CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease. Neurobiol. Aging 28(5), 742–747 (2007).
Medline CASGoogle Scholar
88 Giasson BI, Forman MS, Higuchi M et al. Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 300(5619), 636–640 (2003).
Medline CASGoogle Scholar
89 Shi M, Furay AR, Sossi V et al. DJ-1 and alphaSYN in LRRK2 CSF do not correlate with striatal dopaminergic function. Neurobiol. Aging 33(4), 836 e835–e837 (2012).
MedlineGoogle Scholar
90 Mollenhauer B, Trautmann E, Sixel-Doring F et al. Nonmotor and diagnostic findings in subjects with de novo Parkinson disease of the DeNoPa cohort. Neurology 81(14), 1226–1234 (2013).
MedlineGoogle Scholar
91 Parkinson Progression Marker I. The Parkinson Progression Marker Initiative (PPMI). Prog. Neurobiol. 95(4), 629–635 (2011).
MedlineGoogle Scholar
92 Jellinger KA, Attems J. Neuropathological evaluation of mixed dementia. J. Neurol. Sci 257(1–2), 80–87 (2007).
Medline CASGoogle Scholar
93 Slaets S, Le Bastard N, Theuns J et al. Amyloid pathology influences abeta1–42 cerebrospinal fluid levels in dementia with lewy bodies. J. Alzheimers Dis. 35(1), 137–146 (2013).
Medline CASGoogle Scholar
94 Parnetti L, Castrioto A, Chiasserini D et al. Cerebrospinal fluid biomarkers in Parkinson disease. Nat. Rev. Neurol. 9(3), 131–140 (2013).
Medline CASGoogle Scholar

Vol. 10, No. 1

Metrics

Downloaded 439 times

History

Published online 28 August 2015

Published in print January 2016

Information

Keywords

Financial & competing interests disclosure

This is an EU Joint Programme – Neurodegenerative Disease Research (JPND) project. The project is supported through the following funding organizations under the aegis of JPND – www.jpnd.eu: Denmark (Innovation Fund Denmark); Finland (Academy of Finland, Research Council for Health); Germany (BMBF); Italy (Finanziamento Ministero Salute); The Netherlands: (ZonMw); S Engelborghs is supported by the University of Antwerp Research Fund and the Alzheimer Research Foundation (SAO-FRA). This research has also been co-financed by ERDF (European Regional Development Fund) and Greek national funds through the Operational Program ‘Competitiveness and Entrepreneurship’ of the NSRF (National Strategic Reference Framework); reek national funds through the Operational Program ‘Competitiveness and Entrepreneurship’ of the NSRF (National Strategic Reference Framework). S Engelborghs was/is consultant for Innogenetics/Fujirebio Europe and Roche diagnostics. I Rektorova is supported by the project ‘CEITEC–Central European Institute of Technology’ (CZ.1.05/1.100.02.0068) from the European Regional Development Fund. E Vanmechelen is a co-founder of ADx NeuroSciences. MM Verbeek served on an advisory board for Roche. B Mollenhauer has received independent research grants from TEVA-Pharma, Desitin, Boehringer Ingelheim, GE Healthcare and honoraria for consultancy from Bayer Schering Pharma AG, Roche, AbbVie, TEVA-Pharma, for presentations from GlaxoSmithKline, Orion Pharma, TEVA-Pharma and travel costs from TEVA-Pharma. B Mollenhauer is member of the executive steering committee of the Parkinson Progression Marker Initiative of the Michael J. Fox Foundation for Parkinson's Research and has received grants from the BMBF, EU, Deutsche Parkinson Vereinigung, Michael J. Fox Foundation for Parkinson's Research, Stifterverband für die deutsche Wissenschaft, and has scientific collaborations with Roche, Ely Lilly, BioLegend and Biogen Idec. B Mollenhauer is listed as co-inventors in a patent application to the US Patent Office related to the quantification of α-synuclein in biological fluids for the purpose of improved diagnosis. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

PDF download